Translational Consulting Research
Our Translational Consulting service bridges discovery‑stage research and regulated clinical development by upgrading exploratory assays, biomarker strategies, and analytical approaches into GLP‑ and GCP‑compliant standards. We support early‑stage biotech and pharma companies in transitioning research‑grade methods into robust, regulator‑ready frameworks.
Translational Consulting Research
We can support you with the scientific, technical, and regulatory transition from research assays to GLP/GCP‑ready methodologies, enabling confident progression into early‑phase clinical studies.
- End‑to‑end biomarker strategy from identification to clinical application
- Research assay translation into GLP/GCP‑compliant methods
- Deep infectious disease and immunology expertise
- Dedicated laboratory R&D team (8 PhDs)
- Integrated clinical, analytical, and regulatory capabilities
Translational Assay Readiness
• End‑to‑end biomarker strategy
• Scientific and regulatory consulting
• Assay development and GLP/GCP validation
• PK/PD and translational modelling
• Biomarker endpoint justification
• Phase‑specific analytical planning
• Cross‑functional laboratory and clinical expertise
Reason to Consider hVIVO
1
Extensive experience bridging R&D and clinical development, and proven track record
2
3
Deep immunology and infectious disease expertise
4
Dedicated laboratory project leads (8 PhDs)
For Biotechs
Ideal for early‑stage companies needing translational expertise.
For Pharmaceutical
Organisations advancing complex biomarkers or assays requiring robust qualification.
Development Stages Supported
Preclinical to First-In Human
FAQs
Yes — we specialise in GLP/GCP translation and validation.
Yes — we evaluate scientific relevance and regulatory acceptability.
Yes — we provide scientifically aligned justification text.
Contact Our Translational Consulting Team
